Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (TEST), 2010-2014
2016 (English)In: International Journal of Infectious Diseases, ISSN 1201-9712, E-ISSN 1878-3511, Vol. 49, 141-148 p.Article in journal (Refereed) Published
Background: As part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) we report antimicrobial resistance among Gram-positive and Gram-negative isolates collected globally from integumentary sources between 2010 and 2014. Methods: Minimum inhibitory concentrations and antimicrobial resistance were determined according to Clinical and Laboratory Standards Institute guidelines (US Food and Drug Administration breakpoints against tigecycline). The Cochran-Armitage trend test was used to identify statistically significant changes in resistance. Results: Global rates of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii were 38% and 43%, respectively. No S. aureus isolates were resistant to linezolid or vancomycin; all isolates were susceptible to tigecycline. Two percent of Enterococcus faecalis and 28% of Enterococcus faecium were vancomycin-resistant. Extended-spectrum beta-lactamase (ESBL) producers accounted for 22% of Klebsiella pneumoniae and 16% of Escherichia coli. Resistance to minocycline among E. faecalis, E. faecium, K. pneumoniae, and E. coli decreased significantly (p amp;lt; 0.0001). There were significant increases (p amp;lt; 0.0001) in A. baumannii resistance to cefepime, ceftazidime, ceftriaxone, levofloxacin, meropenem, and piperacillin-tazobactam. Conclusions: Among isolates from integumentary sources, rates of MRSA and ESBL-producing Enterobacteriaceae are stabilizing. Carbapenems and tigecycline have retained their in vitro activity against Gram-positive and Gram-negative organisms. Few agents were active against A. baumannii; its increasing resistance is cause for concern. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Place, publisher, year, edition, pages
ELSEVIER SCI LTD , 2016. Vol. 49, 141-148 p.
Tigecycline; Antimicrobial resistance; Global; Skin and skin structure infections; Surveillance
IdentifiersURN: urn:nbn:se:liu:diva-131178DOI: 10.1016/j.ijid.2016.06.016ISI: 000380806600022PubMedID: 27343986OAI: oai:DiVA.org:liu-131178DiVA: diva2:971975
Funding Agencies|Pfizer Inc.2016-09-192016-09-122016-09-19